Last reviewed · How we verify

NCT07222852: CAPP-E

Cardiovascular Protection After Preeclampsia With Enalapril

Not yet recruiting Phase 3 Last updated 30 October 2025
What this trial tests

Phase 3 trial testing Enalapril in Preeclampsia in 60 participants. Not yet recruiting.

Timeline
15 November 2025
Primary endpoint
15 October 2027
15 October 2027

Quick facts

Lead sponsorWomen and Infants Hospital of Rhode Island
PhasePhase 3
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date15 November 2025
Primary completion15 October 2027
Estimated completion15 October 2027

Drugs / interventions tested

Conditions studied

Sponsor

Women and Infants Hospital of Rhode Island

Who can join

18 and older, female only, with Preeclampsia or Hypertensive Disorder of Pregnancy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to learn if postpartum women are willing to be randomized to different blood pressure medicines after delivery and how that affects blood pressure in women with hypertensive disorders of pregnancy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Enalapril

Trials testing the same drug.

Other recruiting trials for Preeclampsia

Currently open trials in the same condition.

Other Women and Infants Hospital of Rhode Island trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07222852.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing